Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Arphio logo — Rare but not alone

Arphio

Rare but not alone

Founded 2022 Malta Malta 4 employees Health Care, Pharmaceutical

General Information

Company Name Arphio
Founded Year 2022
Location Malta Malta +1
Employees 4
Industries Health Care, Pharmaceutical
Social

Get notified when Arphio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Arphio

Arphio is an orphan pharmaceutical company with the slogan "Rare but not alone." The company is dedicated to enhancing patient access to crucial treatments for rare diseases by partnering with industry experts to identify therapeutics either in development or available in select countries and make them accessible globally. Founded in 2022 by pharmaceutical professionals with extensive expertise, Arphio focuses on rare disease detection, market access, and the international supply of orphan drugs. Headquartered in Malta, the company is powered by DrugsIntel (DI), a data science powerhouse that processes pharmaceutical data from over 75 countries and 6,000 sources to ensure the successful launch of orphan drugs in the market. Arphio aims to address the lengthy diagnostic process for orphan conditions, estimated to take around seven years and visits to 10 different doctors, by leveraging its intelligence tools and partnerships.

Taxonomy: Rare diseases, Orphan pharmaceuticals, Patient access, Drug development, Global market access, Pharmaceutical professionals, Data science, Pharmaceutical data, Market intelligence, Therapeutics, Orphan drug supply, Healthcare industry, Diagnostic expertise

No funding data available for Arphio yet.

Get notified when Arphio raises funding

Arphio Alternatives & Competitors

Arphio vs
Emmes' Rare Disease and Pediatric Center
Emmes' Rare Disease and Pediatric Center United Kingdom

Emmes' Rare Disease and Pediatric Center: dedicated to global clinical development for rare diseases

27 employees
Biotechnology
Arphio vs
DrugsIntel
DrugsIntel Israel

We at DrugsIntel, are providing healthcare organizations an extensive sets of data-driven solutions...

7 employees
Enterprise Software, Information Technology
Arphio vs
Partners4Access
Partners4Access United Kingdom

Global Multi-Award-Winning Access Experts for Orphan Drugs, Cell and Gene Therapies

16 employees
Biotechnology, Pharmaceutical

FAQ About Arphio

Rare but not alone
Arphio was founded in 2022.
Arphio is headquartered in Malta.
Arphio operates in the following industries: Health Care, Pharmaceutical.
Arphio has approximately 4 employees.
Top alternatives and competitors to Arphio include Emmes' Rare Disease and Pediatric Center, DrugsIntel, Partners4Access, S.A.R. PHARMA S.r.l., iniuva. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arphio and Emmes' Rare Disease and Pediatric Center are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Arphio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes